



# Financial Tear Sheet

## Corporate Profile

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders, MN-221 for the treatment of acute exacerbations of asthma, and MN-001 for NASH. MediciNova may pursue development independently or establish a strategic collaboration to support further development of its programs. MediciNova will seek to monetize its other product candidates at key value inflection points. MediciNova's executive management team has extensive global development, regulatory, commercial and financial experience, and manages its international clinical and manufacturing operations through efficient and cost-effective utilization of contract research organizations. Headquartered in La Jolla, California, MediciNova has approximately 15 employees.

## Stock Performance

MNOV (Common)	
Exchange	NASDAQ (US Dollar)
Price	\$9.15
Change (%)	▼ 0.26 (2.76%)
Volume	65,344
Data as of 12/13/18 4:00 p.m. ET	



## Recent News

12/12/18 - 6:00 a.m.

[MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco](#)

10/04/18 - 7:00 p.m.

[MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 \(ibudilast\) for Glioblastoma](#)





09/25/18 - 7:00 p.m.

[MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 \(ibudilast\) in ALS](#)

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form	
10/26/18	<a href="#">8-K</a>	
10/25/18	<a href="#">10-Q</a>	
07/24/18	<a href="#">8-K</a>	
07/23/18	<a href="#">10-Q</a>	

## Corporate Governance

Jeff Himawan, Ph.D.	Chairman of the Board of Directors
Yuichi Iwaki, M.D., Ph.D.	President and Chief Executive Officer, and Founder
Hiroaki Shigeta	Member of the Board of Directors
David O'Toole	Member of the Board of Directors
Kousuke Nakata	Member of the Board of Directors
Yutaka Kobayashi	Member of the Board of Directors

## Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	80	169.49	35.9	15,039,331
Mutual Fund	114	45.43	10.8	4,517,315
Insider *	3	8.53	2.0	854,535

\*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	2,197,289	5.3	26,154	09/30/18
Samurai Investments San Diego, L.L.C.	1,750,000	4.2	750,000	05/09/18
The Vanguard Group, Inc.	1,584,153	3.8	22,432	09/30/18
BlackRock Fund Advisors	1,401,069	3.4	342,250	06/29/18
Kissei Pharmaceutical Co., Ltd.	1,400,000	3.3	0	03/31/18
Essex Woodlands Management, Inc.	1,170,370	2.8	0	09/30/18
Iwaki (Yuichi)	865,594	2.1	0	04/12/18
State Street Global Advisors (US)	658,185	1.6	58,605	09/30/18
Satomi (Hajime)	467,000	1.1	0	05/09/18
Northern Trust Investments, Inc.	464,540	1.1	34,140	09/30/18

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.